Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Dec;47(1):2449580.
doi: 10.1080/0886022X.2025.2449580. Epub 2025 Jan 8.

Efficacy and safety of telitacicept in IgA nephropathy: a real-world study

Lingqiu Dong  1 , Dandan Yang  1 , Aiya Qin  1 , Siqing Wang  1 , Yi Tang  1 , Jiaxing Tan  1 , Wei Qin  1
Affiliations

Efficacy and safety of telitacicept in IgA nephropathy: a real-world study

Lingqiu Dong et al. Ren Fail. 2025 Dec.

Abstract

Background: IgA nephropathy (IgAN) is the most common primary glomerular disease in the world, and specific therapeutic methods for IgAN are limited. Telitacicept is a humanized fusion protein composed of a transmembrane activator and calcium-modulating cyclophilin ligand interactor receptor and human IgG.

Aim: To evaluate the efficacy and safety of telitacicept in adult patients with IgAN in a real-world study.

Methods: Biopsy-proven IgAN patients with 24-hour proteinuria greater than 0.5 g/d who received 240 mg telitacicept weekly were recruited for this study and 1:1:1 matched with patients who received supportive treatment only or immunosuppressive treatment by propensity score matching. The primary outcome was the change from baseline in 24-hour proteinuria over the 3-month follow-up.

Results: Twenty-one patients in each group were enrolled. Telitacicept reduced median proteinuria by 0.72 g/d (54.6%) from baseline, compared with a reduction of 0.18 g/d (20%) in the supportive treatment group and 1.12 g/d (72.1%) in the immunosuppressive treatment group. Preserved eGFR levels were observed in the telitacicept group, whereas eGFR levels decreased in the other two groups. No serious adverse events were observed in the telitacicept treatment group.

Conclusion: Telitacicept may be an effective treatment for IgAN patients by reducing proteinuria and preserving eGFR, and showed a favorable safety profile.

Keywords: BLyS/APRIL inhibitors; IgA nephropathy; kidney function; proteinuria; telitacicept.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
Participant recruitment and exclusion flowchart.
Figure 2.
Figure 2.
Proteinuria levels before and after treatment in the telitacicept group (a) and in each patient (b).
Figure 3.
Figure 3.
Changes in proteinuria and eGFR levels from baseline. Data are expressed as medians and interquartile ranges. (a) Absolute change in 24-h urine protein excretion from baseline; (b) percentage change in 24-h urine protein excretion from baseline; (c) absolute change in eGFR from baseline; (d) percentage change in eGFR from baseline.
See this image and copyright information in PMC

References

    1. Pattrapornpisut P, Avila-Casado C, Reich HN.. IgA nephropathy: core curriculum 2021. Am J Kidney Dis. 2021;78(3):429–441. doi: 10.1053/j.ajkd.2021.01.024. - DOI - PubMed
    1. Zhou F, Zhao M, Zou W, et al. . The changing spectrum of primary glomerular diseases within 15 years: a survey of 3331 patients in a single Chinese centre. Nephrol Dial Transplant. 2009;24(3):870–876. doi: 10.1093/ndt/gfn554. - DOI - PubMed
    1. Zhang L, Wang F, Wang L, et al. . Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379(9818):815–822. doi: 10.1016/S0140-6736(12)60033-6. - DOI - PubMed
    1. Schena FP, Nistor I.. Epidemiology of IgA nephropathy: a global perspective. Semin Nephrol. 2018;38(5):435–442. doi: 10.1016/j.semnephrol.2018.05.013. - DOI - PubMed
    1. Gesualdo L, Di Leo V, Coppo R.. The mucosal immune system and IgA nephropathy. Semin Immunopathol. 2021;43(5):657–668. doi: 10.1007/s00281-021-00871-y. - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources